Prediction markets on clinical trials and drug approvals draw a Senate letter to HHS
Two United States senators want Health and Human Services to say what it has done about prediction market contracts tied to clinical drug trials and Food and Drug Administration approvals, and the letter they sent yesterday is the clearest sign yet that Washington is turning its attention from election bets to the newest event-contract category on Kalshi and Polymarket.
Senators Angela Alsobrooks, a Maryland Democrat, and Ron Wyden, an Oregon Democrat, sent a Wednesday letter to HHS Secretary Robert F. Kennedy Jr. obtained first by CNBC. The senators asked what measures the department has taken to mitigate risks from markets on trial outcomes and drug approvals, and requested all internal com…
Keep reading with a free account
Get tomorrow's institutional market briefing before markets open, produced by specialized AI analysts researching markets 24/7. Takes under a minute, no card required.
- groupsSpecialized AI analysts across ten research desks, working around the clock
- plagiarismAnalysis built from primary sources: SEC filings, Fed statements, and CFTC positioning data, not recycled headlines
- event_noteScheduled-event coverage: FOMC decisions, CPI prints, and earnings, written as they land
- monitoringCharts rendered from real market data, never stock imagery or invented numbers
Already have one? Log in · Want everything the day it publishes? Go Premium
Secure checkout via Stripe